DUBLIN, May 26, 2017 /PRNewswire/ -- Allergan plc (NYSE:
AGN) today announced that it has closed an offering of €2.7 billion
aggregate principal amount of senior unsecured notes (the "Notes")
in 4 tranches in a registered public offering. The Notes have been
issued by its indirect wholly-owned subsidiary, Allergan Funding
SCS (f.k.a. Actavis Funding SCS), and guaranteed by its indirect
subsidiaries Warner Chilcott Limited, Allergan Capital S.à r.l.
(f.k.a. Actavis Capital S.à r.l.) and Allergan Finance, LLC (f.k.a.
Actavis, Inc.), as follows:
Description
|
Principal
Amount
|
Maturity
|
Price to
Public
|
0.500% Senior
Notes
|
€750,000,000
|
Due 2021
|
99.537%
|
1.250% Senior
Notes
|
€700,000,000
|
Due 2024
|
99.355%
|
2.125% Senior
Notes
|
€550,000,000
|
Due 2029
|
99.465%
|
Floating Rate Senior
Notes*
|
€700,000,000
|
Due 2019
|
100.102%
|
______
* The Floating Rate
Senior Notes due 2019 will bear interest at a floating rate
equal to three-month EURIBOR plus 0.350% per annum.
|
The net proceeds from the offering are approximately €2.68
billion after deducting estimated underwriting discounts,
commissions and offering expenses payable by Allergan Funding SCS.
Allergan plc intends to use the net proceeds from the offering of
the Notes to fund the purchase of the existing USD notes validly
tendered and accepted for purchase pursuant to the cash tender
offers (the "Tender Offers") previously commenced on May 10, 2017 by certain of its subsidiaries,
including Allergan Funding SCS, as further described in the offer
to purchase for the Tender Offers, to pay related fees and expenses
and, to the extent of any remaining proceeds, for general corporate
purposes.
Barclays, BNP Paribas, HSBC, and Morgan Stanley (Sole Global
Coordinator) are the joint book-running managers of the offering of
the Notes. Additional joint book-running managers are BofA Merrill
Lynch, Citigroup and Mizuho Securities.
The offering of the Notes was made pursuant to an effective
shelf registration statement filed with the Securities and Exchange
Commission ("SEC"),by means of a prospectus supplement relating to
the offering of the Notes and the accompanying base prospectus,
copies of which may be obtained by contacting: Barclays at
1-888-603-5847, BNP Paribas at 1-800-854-5674, HSBC at
1-866-811-8049, and Morgan Stanley at 1-866-718-1649. These
documents were also filed with the SEC and are available at the
SEC's website at http://www.sec.gov.
This press release does not constitute an offer to sell or
solicitation of an offer to purchase with respect to any existing
debt of Allergan plc or its subsidiaries, nor shall there be any
sale of securities in any state or jurisdiction in which such
offer, solicitation or purchase would be unlawful prior to the
registration or qualification under the securities laws of any such
jurisdiction.
About Allergan plc
Allergan plc (NYSE: AGN),
headquartered in Dublin, Ireland,
is a bold, global pharmaceutical company and a leader in a new
industry model – Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of
research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry with
70+ mid-to-late stage pipeline programs currently in
development.
Allergan's success is powered by our more than 18,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website at
www.Allergan.com.
Forward-Looking Statement
Statements contained
in this press release that refer to future events or other
non-historical facts are forward-looking statements that reflect
Allergan's current perspective on existing trends and information
as of the date of this release. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting the timing or
outcome of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2016 and Allergan's Quarterly Report on Form 10-Q for the
period ended March 31, 2017. Except
as expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
CONTACTS:
|
|
Allergan:
|
|
|
|
Investors:
|
|
|
|
Daphne
Karydas
|
|
|
|
(862)
261-8006
|
|
|
|
|
|
|
|
Media:
|
|
|
|
Mark
Marmur
|
|
|
|
(862)
261-7558
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-announces-closing-of-public-offering-of-senior-notes-to-refinance-existing-debt-300464420.html
SOURCE Allergan plc